PL4253376T3 - Sól i postać krystaliczna pochodnej heterocyklicznej zawierającej azot, sposób jej otrzymywania i jej zastosowanie - Google Patents
Sól i postać krystaliczna pochodnej heterocyklicznej zawierającej azot, sposób jej otrzymywania i jej zastosowanieInfo
- Publication number
- PL4253376T3 PL4253376T3 PL21897144.8T PL21897144T PL4253376T3 PL 4253376 T3 PL4253376 T3 PL 4253376T3 PL 21897144 T PL21897144 T PL 21897144T PL 4253376 T3 PL4253376 T3 PL 4253376T3
- Authority
- PL
- Poland
- Prior art keywords
- nitrogen
- salt
- preparation
- application
- crystal form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011354289 | 2020-11-26 | ||
| CN202111389216 | 2021-11-22 | ||
| PCT/CN2021/133653 WO2022111644A1 (zh) | 2020-11-26 | 2021-11-26 | 含氮杂环类衍生物的盐、晶型及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4253376T3 true PL4253376T3 (pl) | 2025-12-01 |
Family
ID=81753731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21897144.8T PL4253376T3 (pl) | 2020-11-26 | 2021-11-26 | Sól i postać krystaliczna pochodnej heterocyklicznej zawierającej azot, sposób jej otrzymywania i jej zastosowanie |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240325394A1 (pl) |
| EP (1) | EP4253376B1 (pl) |
| JP (1) | JP2023551006A (pl) |
| CN (1) | CN116490188B (pl) |
| AU (1) | AU2021386339A1 (pl) |
| CA (1) | CA3200164A1 (pl) |
| ES (1) | ES3048702T3 (pl) |
| HR (1) | HRP20251311T1 (pl) |
| HU (1) | HUE073345T2 (pl) |
| PL (1) | PL4253376T3 (pl) |
| RS (1) | RS67327B1 (pl) |
| SM (1) | SMT202500386T1 (pl) |
| TW (1) | TW202229278A (pl) |
| WO (1) | WO2022111644A1 (pl) |
| ZA (1) | ZA202306437B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022028346A1 (zh) * | 2020-08-02 | 2022-02-10 | 上海喆邺生物科技有限公司 | 一种芳香类化合物及其在抗肿瘤药物中的应用 |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2025242031A1 (zh) * | 2024-05-20 | 2025-11-27 | 上海翰森生物医药科技有限公司 | 吡啶并[2,3-d]嘧啶-2(1H)-酮类衍生物联合用药在治疗和预防肿瘤疾病中的用途 |
| WO2026026942A1 (zh) * | 2024-08-02 | 2026-02-05 | 江苏豪森药业集团有限公司 | 一种含氮杂环类衍生物的制备方法及其中间体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905676T3 (es) * | 2017-05-22 | 2022-04-11 | Amgen Inc | Inhibidores de KRAS G12C y métodos para su uso |
| CN111051306B (zh) * | 2017-09-08 | 2023-01-03 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
| MX2020010836A (es) * | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| CA3100390A1 (en) * | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
| CN114144414B (zh) * | 2019-05-21 | 2025-11-07 | 美国安进公司 | 固态形式 |
| EP3972972A1 (en) * | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
| CN114437065A (zh) * | 2019-05-21 | 2022-05-06 | 益方生物科技(上海)股份有限公司 | 杂环化合物，其制备方法和用途 |
| WO2020239077A1 (zh) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
| CN112390796B (zh) * | 2019-08-19 | 2023-06-27 | 贝达药业股份有限公司 | Kras g12c抑制剂及其在医药上的应用 |
| EP4092026A4 (en) * | 2020-01-13 | 2024-03-06 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF |
| WO2021185233A1 (en) * | 2020-03-17 | 2021-09-23 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| US20230183235A1 (en) * | 2020-05-20 | 2023-06-15 | Teva Pharmaceuticals International Gmbh | Solid state forms of amg-510 and process for preparation thereof |
-
2021
- 2021-11-26 CA CA3200164A patent/CA3200164A1/en active Pending
- 2021-11-26 JP JP2023532420A patent/JP2023551006A/ja active Pending
- 2021-11-26 TW TW110144262A patent/TW202229278A/zh unknown
- 2021-11-26 EP EP21897144.8A patent/EP4253376B1/en active Active
- 2021-11-26 SM SM20250386T patent/SMT202500386T1/it unknown
- 2021-11-26 PL PL21897144.8T patent/PL4253376T3/pl unknown
- 2021-11-26 AU AU2021386339A patent/AU2021386339A1/en active Pending
- 2021-11-26 HU HUE21897144A patent/HUE073345T2/hu unknown
- 2021-11-26 US US18/254,623 patent/US20240325394A1/en active Pending
- 2021-11-26 HR HRP20251311TT patent/HRP20251311T1/hr unknown
- 2021-11-26 ES ES21897144T patent/ES3048702T3/es active Active
- 2021-11-26 WO PCT/CN2021/133653 patent/WO2022111644A1/zh not_active Ceased
- 2021-11-26 RS RS20251054A patent/RS67327B1/sr unknown
- 2021-11-26 CN CN202180076059.7A patent/CN116490188B/zh active Active
-
2023
- 2023-06-21 ZA ZA2023/06437A patent/ZA202306437B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116490188A (zh) | 2023-07-25 |
| EP4253376A1 (en) | 2023-10-04 |
| WO2022111644A1 (zh) | 2022-06-02 |
| EP4253376A4 (en) | 2024-12-18 |
| EP4253376C0 (en) | 2025-07-30 |
| ZA202306437B (en) | 2025-09-25 |
| SMT202500386T1 (it) | 2025-11-10 |
| EP4253376B1 (en) | 2025-07-30 |
| JP2023551006A (ja) | 2023-12-06 |
| HRP20251311T1 (hr) | 2026-02-27 |
| TW202229278A (zh) | 2022-08-01 |
| ES3048702T3 (en) | 2025-12-11 |
| CN116490188B (zh) | 2026-01-30 |
| HUE073345T2 (hu) | 2026-01-28 |
| AU2021386339A9 (en) | 2025-01-09 |
| CA3200164A1 (en) | 2022-06-02 |
| AU2021386339A1 (en) | 2023-07-06 |
| RS67327B1 (sr) | 2025-11-28 |
| US20240325394A1 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202500386T1 (it) | Forma salina e cristallina di derivato eterociclico contenente azoto, metodo di preparazione per essa e applicazione di essa | |
| EP4328225A4 (en) | HETEROCYCLIC DERIVATIVE INHIBITOR AND ITS PREPARATION METHOD AND APPLICATION | |
| EP4273136A4 (en) | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, METHOD OF PREPARING THE SAME AND MEDICAL USE THEREOF | |
| EP3912976A4 (en) | SALT OF AN EGFR INHIBITOR, CRYSTALLINE FORM AND METHOD FOR PREPARING THEREOF | |
| EP4215244A4 (en) | Triazine compound salt, crystal form thereof, and production method therefor | |
| GB202307487D0 (en) | Method for preparing nitrogen-containing heterocyclic compound and derivative thereof by means of enzymatic-chemical cascade method | |
| EP3763713A4 (en) | CRYSTAL FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND THE METHOD FOR MANUFACTURING IT | |
| IL316662B2 (en) | Method for preparing nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | |
| EP4349828A4 (en) | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PRODUCTION PROCESS THEREOF AND USE THEREOF | |
| IL319797B1 (en) | Method for synthesizing a furoimidazopyridine compound, a crystalline form of a furoimidazopyridine compound, and a crystalline form of a salt thereof | |
| ZA201908433B (en) | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | |
| EP4112052A4 (en) | USE OF AN N-SUBSTITUTED PYRIDYLBENZISOSELENAZOLONE COMPOUND | |
| IL289231A (en) | Salts of compounds, their crystalline forms and their uses | |
| IL314594A (en) | Heterocyclic compounds and methods of use | |
| EP4293021A4 (en) | SALT OF A NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR CRYSTAL FORM THEREOF AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | |
| PT3939977T (pt) | Cristal de composto de amida heterocíclica e método de produção do mesmo | |
| EP4353725A4 (en) | Salt and crystal form of a pyrazole-containing polycyclic derivative, production process therefor, and use thereof | |
| HK40126598A (en) | Salt and crystal form of heterocyclic derivative inhibitor, and preparation method thereof and use thereof | |
| HK40121885A (en) | Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same | |
| CA3271284A1 (en) | Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof | |
| EP4219476A4 (en) | SALT OF A COMPOUND CONTAINING ARYLAMINOCHINAZOLINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | |
| ZA202108765B (en) | Pyridone derivative crystal form and preparation method and application therefor | |
| EP4335850A4 (en) | SALT FORM OF A PYRROLOTRIAZINE COMPOUND, CRYSTAL FORM THEREOF AND METHOD OF PREPARING THE SAME | |
| EP4353729A4 (en) | POLYMORPH OF AN IMIDAZOLIDINONE COMPOUND, METHOD FOR PREPARING THE SAME AND USE THEREOF | |
| CA3274225A1 (en) | Pharmaceutically acceptable salt of nitrogen-containing heterocyclic compound, crystal form thereof, and preparation method therefor |